Drugs / Trivalent Influenza Vaccine (Split Virion)
Trivalent Influenza Vaccine (Split Virion)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07640841 | Jun 2026 → Jun 2027 expected | — | Jiangsu Province Centers for Disease Control and Prevention | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Influenza Vaccine (Split Virion) | “Trivalent Influenza Vaccine (Split Virion), inactivated, produced by Sinovac Biotech Co., Ltd. One dose, intramuscular.” NCT07640841 ↗ |
| Modality | Vaccine | “Trivalent Influenza Vaccine (Split Virion)” NCT07640841 ↗ |
| Route | Intramuscular | “One dose, intramuscular.” NCT07640841 ↗ |